Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR)
and paroxetine on the biotransformation of codeine to morphine in healthy subjects. To assess
the safety and tolerability of DVS SR and paroxetine when coadministered with codeine to
healthy subjects.